the drug discovery process (ppt) - the aps · ppt file · web viewthe drug discovery process ......
TRANSCRIPT
Drug Candidatesafety testing
Animal Studies- relevant species
- transgenic KO/KI mice- conditional KOs
- agonists/antagonists- antibodies- antisense
- RNAi
Studies ofDisease Mechanisms
Human Studies Phases I,II, III
Target-receptor; -ion channel; -transporter;
-enzyme; - signalling molecule
Lead Search-Develop assays (use of automation) -Chemical diversity-Highly iterative processMolecular Studies
The Drug Discovery Process
Lead optimization-selectivity -efficacy in animal models-tolerability: AEs mechanism- based or structure-based?-pharmacokinetics-highly iterative process
Drug Approvaland Registration
Target selection & validation
Discovery Development
Target Selection & Validation Define the unmet medical need (disease) Understand the molecular mechanism of the
disease Identify a therapeutic target in that pathway (e.g
gene, key enzyme, receptor, ion-channel, nuclear receptor)
Demonstrate that target is relevant to disease mechanism using genetics, animal models, lead compounds, antibodies, RNAi, etc.
Discovery Develop an assay to evaluate activity of compounds on the target
- in vitro (e.g. enzyme assay)- in vivo (animal model or pharmacodynamic assay)
Identify a lead compound– screen collection of compounds (“compound library”)– compound from published literature– screen Natural Products– structure-based design (“rational drug design”)
Optimize to give a “proof-of-concept” molecule—one that shows efficacy in an animal disease model
Optimize to give drug-like properties—pharmacokinetics, metabolism, off-target activities
Safety assessment, Preclinical Candidate!!!
Development
Pharmaceutical R&DFormulation
Clinical Investigator& patient
Clinical PharmacologyClinical Research
Statistics & EpidemiologyData CoordinationResearch Information SystemsInformation Services
Regulatory AffairsProject Planning & ManagementMarketing
Process R&DChem Eng. R&DManufacturing
Bio Process R&D
Safety AssessmentToxicology
Drug Metabolism(ADME)
Pharmacology
Pre-Clinical
Clinical
Clinical Trials
Product Profile Marketing SOIProduct Profile Marketing SOI
Information Learned1. Absorption and metabolism2. Effects on organs and tissue3. Side effects as dosage is increased
Information Learned1. Effectiveness in treating disease2. Short-term side effects in health -impaired patients3. Dose range
Information Learned
1. Benefit/risk relationship of drug2. Less common and longer term side effects3. Labeling information
Compassionate Use
Phase IISeveral hundred health-impaired patients
Treatment Group Control Group
Phase IIIHundreds or thousands of health-impaired patients
InvestigationalNew Drug application
IND
Phase I20 - 100 healthy volunteers take drug for about one month
Remote data entry
Clinical Trials
ContinuedAPPROVALPROCESS
(Ex. FDA)
Reviews,comments, and
discussions
Drug Co./Regulatoryliaison activities
APPROVAL
Submit toRegulatory Agencies
AdvisoryCommittee Regulatory
Review Team
New DrugApplication
(NDA)
Worldwide Marketing Authorization (WMA) in other countries
Drug Discovery—Convergence of DisciplinesPatent LawCombinatorial
Chemistry
SyntheticChemistry
PhysicalChemistry
Physiology
Biochemistry
DMPK
Enzymology
Immunology
Pharmacology
InformationTechnology
Modelling
Physiology
SafetyAssessment
Metabolism
Pharmacology
PathologyBehavior
NovelMolecule Intellectual Property
StructuralActivity
PharmacokineticProperties
In Vivo activity
Safety
Design
Pharmaco-
dynamics
Physiology
Physiology
Physiology